.Pharmacolibrary.Drugs.ATC.B.B02BX05 .Pharmacolibrary.Drugs.ATC.B.B02BX05| name: | Eltrombopag |
| ATC code: | B02BX05 | route: | oral |
| n-compartments | 1 |
Eltrombopag is an orally administered thrombopoietin receptor agonist used for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), hepatitis C-associated thrombocytopenia, and severe aplastic anemia. It is approved and marketed for use in several countries.
Pharmacokinetic parameters reported for healthy adult subjects after a single oral dose.
Chen, J, et al., & Ruan, Z (2021). Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability. European journal of drug metabolism and pharmacokinetics 46(3) 427–436. DOI:10.1007/s13318-021-00682-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33779967
Wire, MB, et al., & Brainsky, A (2012). A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clinical therapeutics 34(3) 699–709. DOI:10.1016/j.clinthera.2012.01.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22336488
Dionisi, M, et al., & Goffredo, BM (2021). Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients. Frontiers in pharmacology 12 772873–None. DOI:10.3389/fphar.2021.772873 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34938187